Camrelizumab, formerly known as SHR-1210, represents a significant advancement in malignant treatment, functioning as a biologic that blocks the programmed death-1 receptor. This checkpoint protein, expressed on lymphocytes , normally suppresses anti-tumor immune responses, allowing tumor cells to evade detection by the body’s defenses . By attac